Table of Contents
Overview
New York, NY – July 03, 2025 – Global Diagnostic Contract Manufacturing Market size is expected to be worth around US$ 76.0 Billion by 2034 from US$ 28.5 Billion in 2024, growing at a CAGR of 10.3% during the forecast period from 2025 to 2034. In 2024, North America led the market, achieving over 44.4% share with a revenue of US$ 12.6 Billion.
The global diagnostic contract manufacturing market is witnessing sustained growth as medical device companies increasingly outsource the production of diagnostic instruments, consumables, and test kits to specialized contract manufacturers. This shift is driven by the need for cost optimization, faster time-to-market, and access to advanced manufacturing capabilities.
Diagnostic contract manufacturing services typically include design support, prototyping, assembly, packaging, and regulatory compliance assistance. These services are essential for companies focusing on in-vitro diagnostics (IVD), point-of-care testing (POCT), molecular diagnostics, and immunoassay development. As healthcare systems expand diagnostic capacities to meet public health demands, contract manufacturers play a critical role in supporting mass production, scalability, and global distribution.
Increased prevalence of infectious diseases, cancer, and chronic conditions continues to drive demand for accurate and high-throughput diagnostic tools. According to the World Health Organization (WHO), diagnostics are essential for achieving 46% of universal health coverage targets. As a result, contract manufacturers are expanding capabilities in microfluidics, biosensor integration, and automated test systems.
North America currently leads the market due to its strong medical device infrastructure and regulatory clarity. However, Asia-Pacific is rapidly emerging as a key hub, driven by cost advantages and growing R&D activities. Strategic partnerships, technological innovation, and regulatory alignment are expected to shape the future trajectory of the diagnostic contract manufacturing market.
Key Takeaways
- In 2024, the global diagnostic contract manufacturing market was valued at USD 28.5 billion and is projected to reach approximately USD 76.0 billion by 2034, expanding at a compound annual growth rate (CAGR) of 10.3%.
- Among product types, the in vitro diagnostic (IVD) devices segment held the dominant position in 2024, accounting for 56.2% of the total market revenue.
- Based on application, the cardiology segment led the global market, contributing 38.2% to the overall revenue share in 2024.
- In terms of end-user, diagnostic laboratories emerged as the leading segment, capturing 65.3% of the global market revenue during the same year.
- Regionally, North America secured the largest market share, representing over 44.4% of the total global revenue in 2024.
Segmentation Analysis
- Device Analysis: The diagnostic contract manufacturing market is segmented into in vitro diagnostic (IVD) devices and diagnostic imaging devices. In 2024, IVD devices led the market with a 56.2% revenue share. This dominance is driven by the growing demand for early disease detection, personalized treatment, and decentralized healthcare. CDMOs support OEMs through specialized services like assay development and scalable production. The rise in chronic conditions and advances in home diagnostics and point-of-care testing further strengthen this segment’s future growth prospects.
- Application Analysis: By application, the market includes cardiology, oncology, infectious diseases, and orthopedics. The cardiology segment held the largest share of 38.2% in 2024, owing to the increasing prevalence of cardiovascular disorders. The demand for electrocardiograms, echocardiograms, and cardiac monitors is rising rapidly. CDMOs provide full-scale support, including design, prototyping, and manufacturing. With ongoing innovations like AI integration in diagnostic tools, this segment is poised to remain dominant amid the global burden of heart-related conditions.
- End-User Analysis: The market is segmented by end user into diagnostic laboratories and medical device companies. In 2024, diagnostic laboratories accounted for a dominant 65.3% share. This leadership stems from their pivotal role in developing and producing in vitro diagnostic (IVD) products and laboratory-developed tests. CDMOs enable labs to streamline innovation through design, regulatory, and manufacturing support. Growing interest in point-of-care and personalized diagnostics continues to drive demand, making laboratories key stakeholders in the market’s expansion.
Market Segments
Device
- In Vitro Diagnostic Devices
- Diagnostic Imaging Devices
Application
- Cardiology
- Oncology
- Infectious Diseases
- Orthopedics
End User
- Diagnostic Laboratories
- Medical Device Companies
Regional Analysis
North America accounted for a significant share of the global diagnostic contract manufacturing market in 2024, driven by its well-established healthcare infrastructure, substantial investments in research and development, and the presence of major contract manufacturing organizations. The United States plays a pivotal role in the region’s leadership, supported by a robust regulatory framework that upholds high standards for quality, safety, and compliance in diagnostic device manufacturing.
The growing burden of chronic diseases, such as cardiovascular conditions, cancer, and diabetes, has intensified demand for advanced diagnostic solutions. In parallel, the regional focus on personalized medicine and early disease detection is contributing to the expansion of contract manufacturing services. This environment fosters a high reliance on contract development and manufacturing organizations (CDMOs) to streamline innovation and improve time-to-market.
Prominent players such as Jabil Inc., Flex Ltd., and Plexus Corp. have solidified their presence across the region, offering end-to-end services including design, prototyping, regulatory compliance, and full-scale production. Additionally, the increasing trend of outsourcing among pharmaceutical and diagnostic companies is further reinforcing North America’s dominant role in the global diagnostic contract manufacturing market.
Emerging Trends
- Regulatory Flexibility Drives Outsourcing: The COVID-19 pandemic led the U.S. Food and Drug Administration (FDA) to issue Emergency Use Authorizations (EUAs) that enabled rapid scale-up of test production. By May 2020, the FDA had temporarily authorized diagnostic tests for 84 laboratories and companies, with over 400 additional applications pending. This regulatory flexibility encouraged diagnostic developers to partner with contract manufacturers to meet surging demand. Many CDMOs expanded clean-room and filling capacity by up to 40% between March and June 2020, ensuring timely delivery of test kits to public health labs.
- Expansion of Public Health Laboratory Networks: The Centers for Disease Control and Prevention’s (CDC) Laboratory Response Network (LRN) has grown from a handful of federal and state labs in 1999 to include over 150 domestic and international laboratories. By early June 2022, LRN members could process up to 8,000 tests per week an increase from 6,000 tests weekly before the 2022 mpox outbreak. Contract manufacturers now work closely with LRN labs to supply reagents and consumables, supporting this expanded capacity.
- Integration of High-Throughput and Digital Tools: Advances in automation have enabled contract manufacturers to adopt high-throughput filling lines capable of packaging tens of thousands of test tubes per day. The CDC’s Antimicrobial Resistance Lab Network repurposed sequencing platforms to process over 4,700 SARS-CoV-2 genomes in 2020, demonstrating the benefits of shared digital infrastructure. These investments in robotics and informatics improve batch tracking and reduce turnaround times for new diagnostic product launches.
- Government-Backed Production Partnerships: U.S. government solicitations under SAM.gov have required manufacturers to establish “sufficient production capacity to meet outbreak response needs” as identified by the CDC. These contracts often include milestone-based payments tied to capacity build-out. As a result, many contract manufacturers have added modular clean rooms and automated reagent preparation lines, boosting overall output by 25–30%.
Use Cases
- Rapid COVID-19 Test Kit Production: During the early pandemic phase, the CDC shipped sample panels to LRN labs to validate new assays. Contract manufacturers filled and labeled over 50 million molecular test kits between April and December 2020 to support this effort. Their flexible manufacturing lines enabled turnaround of next-day production scale-ups, ensuring that public health labs nationwide could perform tests without supply interruptions.
- Multiplex Respiratory Panels for Surveillance: To monitor multiple pathogens in a single assay, contract manufacturers produce multiplex respiratory panels. For example, by mid-2021, CLRN’s SARS-CoV-2 Proficiency Test Program which delivered three rounds of test samples saw participation increase by over 400%, demonstrating demand for broad surveillance tools. These panels allow labs to detect influenza A/B, RSV, and SARS-CoV-2 in one run, reducing labor and reagent costs by up to 30%.
- Genomic Sequencing Kits for Outbreak Response: The CDC’s AR Lab Network repurposed its sequencing capacity to support COVID-19 genomic surveillance. Contract manufacturers supplied over 5,000 customized library prep kits in 2020, facilitating the sequencing of 4,700 SARS-CoV-2 genomes. These kits included pre-aliquoted reagents and barcoding primers, enabling decentralized labs to join national surveillance efforts rapidly.
- Emergency Stockpile Maintenance: Under HHS contracts, manufacturers produce and replenish strategic stockpiles of diagnostic reagents. A recent CDC cooperative agreement funded $2.1 billion to enhance detection through the Coronavirus Response and Relief Supplemental Funds, which supported contract-manufactured reagent buffers and controls. This ensures that, in the next public health emergency, critical test components can be deployed within days.
Conclusion
The global diagnostic contract manufacturing market is poised for sustained growth, driven by rising demand for scalable, cost-efficient, and technologically advanced diagnostic solutions. Outsourcing trends are accelerating as medical device companies seek speed, flexibility, and regulatory support in product development.
The dominance of IVD devices and diagnostic laboratories, coupled with North America’s leadership and Asia-Pacific’s emerging potential, underscores the sector’s global relevance. Strategic investments in automation, public health partnerships, and digital infrastructure continue to enhance production capacity. Backed by strong government support and evolving healthcare needs, contract manufacturers will remain vital to advancing global diagnostic capabilities.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
